New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and SCORED Phase 3 outcomes studies of its investigational sotagliflozin product at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois
By Lexicon Pharmaceuticals, Inc.
Published - Oct 31, 2022, 09:05 AM ET
Last Updated - Jul 22, 2024, 04:04 AM EDT
THE WOODLANDS, Texas, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and SCORED Phase 3 outcomes studies of its investigational sotagliflozin product at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois.
The following analyses of sotagliflozin have been selected for oral and poster presentations: